AURKA and hematologic disorder: Alisertib (MLN8237) is a selective small molecular Aurora-A kinase inhibitor that is investigated for treatment as a single agent or in combination with other agents across a range of solid and hematologic malignancies (Manfredi et al., 2011; Venkatakrishnan et al., 2015; Tayyar et al., 2017).